
Heart Failure Drugs in the Pipeline: Six Novel Therapeutics to Note
Heart failure drugs in the pipeline now number more than 100 and include familiar names plus dozens of new ones. Get a top-line look at 6 of the most promising.
Heart failure drugs in the pipeline now number more than 100 and reflect research ongoing at more than 100 pharmaceutical companies.
Spanning developmental stages, they include familiar agents such as omecamtiv mecarbil and investigational molecules, including a β3-adrenergic receptor antagonist and cardiac myotrope.
A report from market research company DelveInsitght,
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.


























































































































































































































































































